Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents
Radiat Res. 2021 Sep 23. doi: 10.1667/RADE-21-00169.1. Online ahead of print.ABSTRACTTreatment of accidental radiation-induced myelosuppression is primarily based on supportive care and requires specific treatment based on hematopoietic growth factors injection or hematopoietic cell transplantation for the most severe cases. The cytokines used consisted of pegylated erythropoietin (darbepoetin alfa) 500 IU once per week, pegylated G-CSF (pegfilgrastim) 6 mg × 2 once, stem cell factor 20 μg.kg-1 for five days, and romiplostim (TPO analog) 10 μg.kg-1 once per week, with different combinations depending on the accidents. A...
Source: Radiation Research - September 23, 2021 Category: Physics Authors: Marc Benderitter Eduardo Herrera-Reyes Yvan Gigov Bertrand Souleau Jean Christelle Huet Fran çois Trompier Thierry Fagot Eric Gr égoire Jean Val ère Malfuson Johanna Konopacki-Potet Elena Buglova Jean-Jacques Lataillade Radia Tamarat Patrick Gourmelon Source Type: research
